» Articles » PMID: 24215230

Pathogenic Immune Mechanisms at the Neuromuscular Synapse: the Role of Specific Antibody-binding Epitopes in Myasthenia Gravis

Overview
Journal J Intern Med
Specialty General Medicine
Date 2013 Nov 13
PMID 24215230
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Autoantibodies against three different postsynaptic antigens and one presynaptic antigen at the neuromuscular junction are known to cause myasthenic syndromes. The mechanisms by which these antibodies cause muscle weakness vary from antigenic modulation and complement-mediated membrane damage to inhibition of endogenous ligand binding and blocking of essential protein-protein interactions. These mechanisms are related to the autoantibody titre, specific epitopes on the target proteins and IgG autoantibody subclass. We here review the role of specific autoantibody-binding epitopes in myasthenia gravis, their possible relevance to the pathophysiology of the disease and potential implications of epitope mapping knowledge for new therapeutic strategies.

Citing Articles

Myasthenia Gravis Treatment: From Old Drugs to Innovative Therapies with a Glimpse into the Future.

Crisafulli S, Boccanegra B, Carollo M, Bottani E, Mantuano P, Trifiro G CNS Drugs. 2024; 38(1):15-32.

PMID: 38212553 DOI: 10.1007/s40263-023-01059-8.


Immunotherapies in MuSK-positive Myasthenia Gravis; an IgG4 antibody-mediated disease.

Vakrakou A, Karachaliou E, Chroni E, Zouvelou V, Tzanetakos D, Salakou S Front Immunol. 2023; 14:1212757.

PMID: 37564637 PMC: 10410455. DOI: 10.3389/fimmu.2023.1212757.


Serum neurofilament light chain in myasthenia gravis subgroups: An exploratory cohort and case-Control study.

Stascheit F, Aigner A, Mergenthaler P, Hotter B, Hoffmann S, Lehnerer S Front Neurol. 2023; 13:1056322.

PMID: 36712429 PMC: 9875128. DOI: 10.3389/fneur.2022.1056322.


Protein therapeutics and their lessons: Expect the unexpected when inhibiting the multi-protein cascade of the complement system.

Schmidt C, Smith R Immunol Rev. 2022; 313(1):376-401.

PMID: 36398537 PMC: 9852015. DOI: 10.1111/imr.13164.


Neonatal Fc Receptor-Targeted Therapies in Neurology.

Nelke C, Spatola M, Schroeter C, Wiendl H, Lunemann J Neurotherapeutics. 2022; 19(3):729-740.

PMID: 34997443 PMC: 9294083. DOI: 10.1007/s13311-021-01175-7.